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Aims: Elderly patients with heart failure with reduced ejection fraction (HFrEF) have worse 
prognosis and less often receive guideline-recommended therapies. We aim to better 
understand the underlying pathophysiological processes associated with aging in HFrEF 
potentially leading to targeted therapies in this vulnerable population. 
Methods and Results: From a panel of 363 cardiovascular biomarkers available in 1,611 
patients with HFrEF in the BIOSTAT-CHF index cohort and cross-validated in 823 patients in 
the BIOSTAT-CHF validation cohort, we tested which biomarkers were dysregulated in 
patients aged>75yr versus <65yr. Secondly, pathway overrepresentation analyses were 
performed to identify biological pathways linked to higher plasma concentrations of 
biomarkers in elderly versus younger patients. After adjustment, multiple test correction 
(FDR 1%), and cross-validation, 27/363 biomarkers were associated with older age, 22 
positively, and 5 negatively. The biomarkers that were positively associated with older age 
were associated with tumor cell regulation, extra-cellular matrix organization, and 
inflammatory processes, whereas biomarkers negatively associated with older age were 
associated with pathways that may point to cell proliferation and tumorigenesis.  Among 
the 27 biomarkers, WFDC2 (WAP Four-Disulfide-Core-Domain-2) – that broadly functions as 
a protease inhibitor - was associated with older age and had the strongest association with 
all outcomes. No protein-by-sex interaction was observed.  
Conclusions: In elderly HFrEF patients, pathways associated with extra-cellular matrix 
organization, inflammatory processes, and tumor cell regulation were activated, while 
pathways associated with tumor proliferation functions were down-regulated. These 
findings may help in a better understanding of the aging processes in HFrEF and identify 
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Elderly patients with heart failure with reduced ejection fraction (HFrEF) have worse 
prognosis and less often receive guideline-recommended therapies. Using a large set of 
circulating proteins, elderly patients had higher concentrations of proteins associated with 
tumor cell regulation, extra-cellular matrix organization, and inflammatory processes, 
whereas pathways that may point to cell proliferation and tumorigenesis were down-
regulated.  WAP Four-Disulfide-Core-Domain-2 was associated with older age and had the 
strongest association with an increased risk of all outcomes. Understanding the underlying 
pathophysiological processes associated with aging in HFrEF may potentially lead to 








The average lifespan of the human population is increasing worldwide. It is estimated that 
25% of the world population will be older than 65 years by 2030. Age is the main risk factor 
for the development of cardiovascular diseases; hence, their prevalence increases 
dramatically with aging1. Heart failure (HF), in particular, is a cardiovascular disease 
epidemic that affects 1-2% of the adult population in developed countries and rises above 
10% among the elderly2, 3. Age-related physiological changes, multi-comorbidity, frailty, and 
polypharmacy, all contribute to a poor prognosis and can alter drug pharmacokinetics (and 
change the effect of treatments) in elderly HF patients4. Moreover, the functional decline is 
more accelerated in some individuals than in others. In other words, the biological and 
chronological age are not aligned in all individuals5. With the increasing HF prevalence 
among the elderly, it becomes relevant to better understand the mechanisms underpinning 
biological aging in this population; as this may lead to novel targeted interventions and 
therapies that may reduce the burden of the disease.  
 Circulating biomarkers that reflect the aging process in HF, can provide a useful tool 
for early detection of high-risk patients regardless of their chronological age. Beyond their 
prognostic performance, these biomarkers should provide insight into the cellular and 
molecular mechanisms that underlie aging, disease-specific pathways, and prognosis6. Aging 
affects the levels of circulating proteins that are strongly associated with the prognosis of HF 
patients7. Because single-molecule biomarkers are unlikely to explain the complexity of the 
aging-related processes, a “multi-omics” approach may provide a more comprehensive 
“blueprint” of aging8.  
 Using two independent cohorts of patients with heart failure with reduced ejection 
fraction (HFrEF), we sought to investigate the circulating proteomic biomarkers associated 
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with aging, their prognostic implications and underlying mechanistic pathways using 
pathway analysis.  
 
Methods 
Patient population  
BIOSTAT-CHF is a European project that enrolled 2,516 patients with worsening HF on less 
than guideline-recommended doses of medication from 69 centres in 11 European 
countries, to investigate the factors predicting the response to attempted up-titration of HF 
therapies. The design and first results of the study and patients have been published9.  
Index cohort 
Briefly, patients were aged ≥18 years with signs and symptoms of worsening HF managed 
either in an out-patient clinic or hospital ward. The diagnosis of HF was confirmed either by 
a left ventricular ejection fraction (LVEF) of ≤40% or a BNP and/or NT-proBNP plasma levels 
>400 pg/mL and/or >2000 pg/mL, respectively. Patients needed to be treated with either 
oral or intravenous furosemide ≥40 mg/day or equivalent at the time of inclusion. Patients 
were either treatment naïve with respect to disease-modifying therapies (ACEi/ARBs and 
beta-blockers) or were receiving <50% of the target doses of at least one of these drugs at 
the time of inclusion10. Patients with an active cancer or with an expected survival of less 
than six months were excluded from the study. The recruitment period lasted 24 months. 
The median (pct25-75) follow-up time was 21 (9-26) months. In the present analysis we used 
the 1,611 patients who had both HFrEF (defined by HF and a LVEF ≤40%) and circulating 




Our results were cross-validated (double cross-validation) with the BIOSTAT-CHF validation 
cohort, that was designed as a multicentre, prospective, observational study consisting of 
1,738 patients from six centres in Scotland, UK. Median follow-up was 21 months. Patients 
from the validation cohort were aged >18 years with a HF diagnosis based on 
echocardiographic evidence of left ventricular dysfunction or a previous documented 
admission with HF treated with furosemide ≥20 mg/day or equivalent. They were not 
previously treated or receiving ≤50% of target doses of ACE inhibitors/ARBs and/or beta-
blockers according to the 2008 European Society of Cardiology guidelines. Patients could be 
enrolled as inpatients or from outpatient clinics9. In the present analysis we used the 823 
patients who had HFrEF and circulating biomarkers measured (i.e., using the same 
definitions as in BIOSTAT-CHF index cohort).  
Study outcomes 
The primary outcome was a composite of heart failure hospitalization and all-cause 
mortality. The adjudication of HFH was performed by the treating physician. After the trial 
had ended all medical reports of the mortality events were read and adjudicated based on 
the medical registries from the case report forms, and the cause of death was ascertained 
and inserted in the dataset as cardiovascular or non-cardiovascular.  
This study was conducted according to good clinical practice guidelines and 
approved by the relevant Ethics Committee at each institution and by Regulatory Authorities 
in each country. All patients provided written, informed consent prior to enrolment in the 
study. This study was conducted in conformity with the principles outlined in the 
Declaration of Helsinki.  
Circulating biomarkers 
 Four protein biomarker panels with 92 biomarkers each (n =363, due to 5 overlapping 
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proteins) from a wide range of pathophysiological domains were measured using Olink® 
technology (CVDII, CVDIII, immune-response, and immuno-oncology panels: 
https://www.olink.com/). These panels were selected because they contain known human 
cardiovascular, inflammatory and oncologic markers as well as some exploratory human 
proteins which may have potential as new markers of cardiovascular disease. The 
biomarkers were measured (in each panel) using a high-throughput technique using the 
Olink Proseek® Multiplex 96x96 kit, which measures 92 manually-selected proteins 
simultaneously in 1μl of plasma. The kit uses a proximity extension assay (PEA) technology, 
where 92 oligonucleotide-labeled antibody probe pairs are allowed to bind to their 
respective target present in the sample. PEA is a homogeneous assay that uses pairs of 
antibodies equipped with DNA reporter molecules. When binding to their correct targets, 
they give rise to new DNA amplicons each ID-barcoding their respective antigens. The 
amplicons are subsequently quantified using a Fluidigm BioMark™ HD real-time PCR 
platform. The platform provides Log2 normalized protein expression (NPX) data wherein a 
high protein value corresponds to a high protein concentration, but not an absolute 
quantification.  
The collection of the clinical, biological and biomarker data presented in this analysis 
was performed at baseline i.e. in the first study visit.  
Statistical and bioinformatics analyses 
Population description and comparison of the patients` characteristics by tertiles of age 
(<65yr; 65-75yr; and >75yr) was performed using parametric or non-parametric tests, as 
appropriate.  
 Multinomial logistic regression models were used with the younger age category 
(<65yr) set as reference and the older age category (>75yr) set as the main comparator to 
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obtain a comparison of the elderly vs. young. The age models were extensively adjusted for 
potential confounders including, sex, body mass index (BMI), heart rate, systolic blood 
pressure (SBP), peripheral edema, ischemic etiology, prior revascularization, atrial 
fibrillation, diabetes, chronic obstructive pulmonary disease (COPD), anemia, urea, renal 
function (estimated glomerular filtration rate, eGFR by the CKD-EPI formula), albumin, 
outpatient vs. inpatient setting, NYHA functional class, prior HF hospitalization, stroke, and 
peripheral artery disease. A multiple test correction for false discoveries was applied using 
the Benjamini-Hochberg method, and a false discovery rate was set at 0.01 (i.e., FDR1%)11. 
The results were cross-validated with the validation cohort i.e., the results were tested in 
BIOSTAT-CHF index cohort and validated in BIOSTAT-CHF validation cohort and vice-versa. 
For robustness of results we present (in the manuscript main tables) the biomarkers that 
passed the adjustment for confounders plus multiple test correction plus the bidirectional 
cross-validation. To assess if the biomarker expression could vary by sex, we performed a 
sex-by-biomarker interaction in the model but none was present. Cox proportional-hazards 
models were used to study the association between the biomarkers (previously found to be 
independently associated with age) and outcomes; the same adjustment, correction and 
validation principles were applied. Since proteins were measured using NPX (Normalized 
Protein eXpression) values on a Log2 scale, the hazard ratio for each protein estimates the 
increase in the hazards of event associated with a doubling in the protein concentration. 
 To study the underlying mechanistic pathways of the most dysregulated proteins 
associated with age, we created a general network of human physical protein-protein 
interactions (PPIs), ‘HsapiensPPI’, consisting of unique nodes and PPIs based on data from 
BIND, BIOGRID, DIP, HPRD, INTACT and pdzBase. Context-specific networks were 
constructed by selecting nodes and interactions that occur only between members from the 
11 
 
protein list being investigated (N0-networks) and/or by selecting nodes that indirectly 
interact, one-neighbour-away, with members of the list (N1- networks). Physical 
cohesiveness of context-specific networks was assigned using the Physical Interaction 
Enrichment (PIE) procedure that corrects for biased enrichment12. 
Protein interaction networks were plotted using Cytoscape version v3.7.2, and pathway 
overrepresentation analyses were done using the Cytoscape-plugin ClueGO version v2.5.6 
and Cluepedia version v1.5.613. Annotations are based on Gene Ontology, KEGG and 
Reactome pathways as source databases. These three resources were updated on 26-
March-2020 before the analyses. Enrichment analyses settings were as follows: Go-term 
fusion used to minimize term redundancy, and reported only results p<0.05. The rest were 
left at recommended default settings. 
Analyses were performed using Stata® (version 16) and R® (version 3.6.2). The level 
of significance was based on the assumptions above defined and was generally lower than 
0.001. 
Data Availability Statement 





Compared with younger patients (<65yr), the older ones (>75yr) were more often female, 
had lower BMI, eGFR, albumin levels, higher SBP, more severe signs and symptoms of HF 
and more co-morbid conditions. Similar characteristic patterns were observed in both 
cohorts. Table 1 & Supplemental Table 1.  
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Biomarkers independently associated with age 
After the extensive adjustment, correction and cross-validation described in the methods 
section. The biomarkers positively associated with older age (>75yr) were: decorin (DCN), 
interleukin 17d (IL17D), matrix metalloproteinase 12 (MMP12), insulin growth factor 
binding-protein 2 (IGFBP2), osteoprotegerin (OPG), metalloproteinase inhibitor 4 (TIMP4), 
R-spondin-3 (RSPO3), chitotriosidase-1 (CHIT1), myoglobin (MB), neurogenic locus notch 
homolog protein 3 (NOTCH3), tumor necrosis factor ligand superfamily member 13 
(TNFSF13), triggering receptor expressed on myeloid cells 1 (TREM1), fc receptor-like 
protein 6 (FCRL6), pancreatic prohormone (PPY), stem cell factor (SCF), integrin beta-5 
(ITGB5), TF protein (TF), alpha-1-microglobulin/bikunin precursor (AMBP), C-X-C motif 
chemokine 13 (CXCL13), WAP four-disulfide core domain protein 2 (WFDC2), TGF-beta 
receptor type-2 (TGFR2), and prolargin (PRELP). Table 2.   
The biomarkers negatively associated with older age were: receptor tyrosine-protein 
kinase erbB-3 (ERBB3), c-type lectin domain family 4 (CLEC4G), receptor tyrosine-protein 
kinase erbB-2 (ERBB2), hydroxyacid oxidase 1 (HAOX1), and signalling threshold regulating 
transmembrane adaptor 1 (SIT1). Table 2. BNP was not independently associated with older 
age.   
The complete biomarker lists are presented in the Supplemental Material (Tables 2 
to 4).  
Biomarkers independently associated with both age and outcomes 
The biomarkers positively associated with the study outcomes were: 1) all-cause death or 
HF hospitalization: WFDC2, PRELP, TREM1, ITGB5, and CXCL13; 2) all-cause death: WFDC2, 
DCN, TNFSF13, TREM1, RSPO3, PRELP, CXCL13, ITGB5, OPG, and NOTCH3; 3) cardiovascular 
death: WFDC2, TNFSF13, TREM1, CXCL13, RSPO3, and ITGB5; 4) non-cardiovascular death: 
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WFDC2, IGFBP2, TREM1, TNFSF13, DCN, PRELP, OPG, TGFR2, and RSPO3. Table 3. WFDC2 
had the strongest associations with all the outcomes. SCF was negatively associated with all-
cause death alone. The circulating proteins CXCL13 and ITGB5 were associated with 
cardiovascular death but not with non-cardiovascular death. Table 3.  
Network Analysis 
In the enriched networks and corresponding over-represented pathways, the proteins 
ERBB2, ERBB3, and CLEC4G played a central role and could point towards cancer-related 
processes. The remaining proteins with positive associations with older age were mostly 
implicated in pathways related to tumor cell regulation, collagen metabolism/extra-cellular 
matrix organization and inflammation. Figure 1A-C. The main findings are resumed in the 
Central Illustration.  
 
Discussion 
The main finding of the present study is that elderly HFrEF patients (compared to younger 
patients) showed activated pathways that are linked to tumor cell regulation, collagen 
metabolism/extra-cellular matrix organization and inflammation. Oppositely, pathways 
related to cancer and tumorigenesis had lower expression in older HFrEF patients. 
Furthermore, a higher expression of pro-inflammatory and pro-fibrotic markers were 
associated with poor outcomes, with the exception of SCF, which higher expression could be 
associated with a lower risk of subsequent death. WFDC2 was both associated with older 
age and had the strongest association with all outcomes.  
Aging is characterized by a progressive loss of physiological integrity, leading to 
impaired function and ultimately death14. Aging affects the levels of circulating proteins, 
metabolites and other molecules that may underpin extra-cellular (e.g., collagen integrity), 
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cellular (e.g., clonal cell expansion), epigenetic (e.g., DNA methylation) and genetic 
alterations (e.g., telomere attrition, DNA mutations)8. A deeper understanding of the 
interconnectivity of the aging processes is essential for the development of better 
prevention strategies and pharmaceutical targets. Heart failure develops through complex 
interactions of the cardiovascular aging process with risk factors (i.a. obesity, hypertension, 
and atherosclerosis), comorbidities (i.a. anemia, chronic kidney disease, diabetes), and 
disease modifiers (i.a. sex, genes, therapies)15. In this regard, our study analyzed 363 
circulating proteins in two independent cohorts of HFrEF to provide a comprehensive and 
integrative approach on the aging process of HFrEF patients. It should be noted that all 
these patients already have major hallmarks of biological aging, as they have symptomatic 
HF and other vascular/atherosclerotic aging features (e.g., myocardial infarction, stroke, 
peripheral artery disease). However, even in the presence of advanced biological aging (and 
adjusting for major potential confounders), circulating biomarkers could identify patients 
with different biological signatures. Proteins as ERBB2, ERBB3, and CLEC4G had a negative 
association with older age; these proteins point towards cancer-related processes and have 
been implicated in the pathogenesis of multiple cancer types. Of note, HF and cancer are 
associated with each other, and recently, it has been appreciated that incident cancer is 
considerably more common in patients with HF than in age and sex-matched subjects 
without HF16-18. Indeed, it appears this association is stronger in relatively younger patients 
with HF than in the (very) elderly (>75yr). The mechanisms for this finding are complex, but 
circulating HF associated factors have been identified, and these have been causally linked 
to tumor growth. In prevalent HF, cancer associated pathways appear to be upregulated 
and may be sensed by tumor biomarkers19. It is thus possible, albeit speculative, that HFrEF 
patients reaching very old age are those less likely to have had a previous malignancy, which 
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may explain the lower expression of some (but not all) cancer-associated proteins and also 
the long-term survival of these patients.  
ERBB2, also commonly referred to as HER2 (from human epidermal growth factor 
receptor 2) or HER2/neu, is a protein that in humans is encoded by the ERBB2 gene. This 
gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor 
tyrosine kinases. Amplification and/or overexpression of this gene has been reported in 
numerous adenocarcinomas (including breast, ovarian, gastric, lung, bladder, prostate, 
uterus, and bone). In recent years the protein has become an important biomarker and 
target of therapy for approximately 30% of breast cancer patients and these mutations have 
shown sensitivity to certain tyrosine kinase inhibitors (e.g., neratinib)20. The dual role of 
ERBB2 in tumor growth and in physiological adaptive reactions of the heart positions ERBB2 
at the intersection between cancer and chronic HF. ERBB2-targeted inhibitory therapy of 
cancer may induce ventricular dysfunction, and activation of ERBB2 for HF therapy may 
increase the risk of malignancy. However, the molecular processes leading to the activation 
of ERBB2 in cancer and heart are different, suggesting that it might be feasible to design 
drugs that specifically target either individual signaling pathway, activating ERBB2 signaling 
in HF without increasing the risk of cancer21. The ERBB3 (erbB family receptor tyrosine 
kinase 3) or HER3, plays a central role as cell surface receptor for neuregulins and is involved 
in the regulation of myeloid cell differentiation. Amplification of this gene and/or 
overexpression of its protein have been reported in numerous cancers, including prostate, 
bladder, and breast tumors22. The CLEC4G encodes a glycan-binding receptor and is a 
member of the C-type lectin family which plays a role in the T-cell immune response, and 
binds to mannose, fucose and N-acetylgalactosamine units that expressed in a variety of 
carcinoma cells23. HAOX1 and SIT1 are involved in T-cell regulation and other inflammatory 
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pathways that might contribute to the pathophysiological features of cardiovascular disease 
and cancer16.  
The biomarkers positively associated with older age point towards processes linked 
to chronic low-grade inflammation, fibrosis and excessive oxidative stress superimposed on 
a limited capacity for cardiac regeneration24. Additionally, we have found that WFDC2 and 
TREM1 were independently associated with both older age and major adverse outcomes, 
including cardiovascular and all-cause mortality. WFDC2 (or epididymal secretory protein 
E4) is a member of the group of serine protease inhibitors belonging to the WAP family25. 
The WFDC2 gene is expressed in pulmonary epithelial cells preserving the integrity of tight 
junctions between epithelial cells, inhibits bacterial growth and prevents invasion by 
commensal bacteria and mucosal inflammation in colonic epithelial cells26. WFDC2 is also 
considered an important biomarker for an early diagnosis of ovarian cancer27. Markedly, 
WFDC2 is amongst the strongest predictors of poor outcome in HF, again underscoring the 
intimate relation between HF and cancer28. TREM1 stimulates neutrophil and monocyte-
mediated inflammatory responses, serving as an amplifier of inflammatory responses that 
are triggered by bacterial and fungal infections and is a crucial mediator of septic shock29. 
The main pathways associated with these proteins – epithelial cell integrity and 
inflammatory response to infections - may explain why these proteins were associated with 
all causes of death, including non-cardiovascular. On the other hand, the circulating proteins 
chemokine CXCL13 and ITGB5 were strongly associated with cardiovascular death but not 
with non-cardiovascular death. CXCL13 is a chemokine highly expressed by stromal tissue 
and follicular dendritic cells, where, along with its receptor CXCR5, it is essential for the 
guidance of B lymphocytes to secondary lymphoid organs. The CXCL13-CXCR5 chemokine 
axis has been associated with various inflammatory conditions, and is strongly expressed in 
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human atherosclerotic lesions and increased in plasma of patients with carotid 
atherosclerosis; suggesting a potential role for the CXCL13-CXCR5 chemokine axis in 
atherosclerosis30, 31. The integrin ITGB5 is a cell-surface receptor that participates in cell 
adhesion and cell-surface mediated signalling. Its expression has been associated with 
arrhythmogenic right ventricular cardiomyopathy, coronary artery disease, atrial fibrillation 
and HF32. In this case, the main pathways associated with these proteins – atherosclerosis 
and cardiac dysfunction - may explain why these proteins were associated with 
cardiovascular death but not non-cardiovascular death.  
The only protein with a negative association with all-cause death (but not retained 
for the other outcomes) was SCF (or c-KIT ligand). SCF is required for hematopoiesis and 
plays an essential role in the regulation of cell survival and proliferation. Downregulation of 
SCF-c-kit decreased engraftment of transplanted bone marrow stem cells in infarcted rat 
hearts33. These findings may help explaining why higher concentrations of this marker are 
associated with lower all-cause death rates.  
Limitations 
Several limitations should be acknowledged in this analysis. This is a post-hoc observational 
analysis, therefore all limitations inherent to such analyses are applied herein, including the 
inability to infer causality; these findings should be regarded as hypothesis generating. To be 
enrolled in BIOSTAT-CHF patients could not have a known active malignancy, hence these 
findings may not reflect “real-world” HF patients who may have higher risk of cancer. 
Moreover, the expression of cancer-related biomarkers was not consistent for all the 
studied biomarkers. For example, ERBB family proteins were negatively associated with 
older age, but WFDC2 was positively associated with older age and also the study outcomes. 
Having a population of patients with HFrEF and a malignancy would provide further insight 
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about the cancer/age-related pathways. These biomarkers are expressed in arbitrary Log2 
normalized NPX units (as detailed in the methods section), therefore the inference of a 
ready-to-use clinical biomarker “unit” is not possible at this stage. Despite having measured 
363 circulating proteins, we cannot ascertain whether a wider set of circulating proteins 
would provide additional information including different age associated-mechanisms. Some 
of the mechanisms and pathways intersect (e.g., inflammation, atherosclerosis and 
tumorigenesis) which may reflect the complexity of HFrEF in humans and the interplay 
between many co-morbid conditions. This study lacks specific cancer diagnosis as it was not 
designed for that purpose, and many of these patients could have undiagnosed or low-
grade cancers that contributed to the expression of some of these markers. The event 
adjudication ascertained death from cardiovascular and non-cardiovascular causes, but the 
specific mode of death (e.g., cancer) was not captured. Importantly, we do not have an 
age/sex matched control group who did not have HF - so we do not know whether these 
differences are specific for HF or apply more generally to aging. The bioinformatic approach 
used is limited to the expressed circulating proteins and may not reflect the relevant intra-
cellular mechanisms of aging in patients with HFrEF. Lastly, HF may be a survivor 
characteristic where only people who lived long enough can have HF, hence the lower 
expression of cancer-related pathways may reflect this survivor bias by selecting only the 
people who did not die of cancer earlier. 
 
Conclusion 
Elderly HFrEF patients may express higher levels of proteins associated with extra-cellular 
matrix organization, inflammatory processes, and tumor cell regulating functions, and may 
express lower levels of proteins associated with tumor proliferation functions. The role of 
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WFDC2 in HFrEF should be furtherly explored. These findings may help in a better 
understanding of the aging processes in HFrEF and identify potential therapeutic targets.  
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Table 1. Patients` characteristics by age tertiles (BIOSTAT-CHF) 
Patients` characteristics <65yr 65-75yr >75yr p-value 
N. (Total =2008) 788 673 547 
 
Age, yr 55.2 ± 7.9 70.2 ± 3.3 80.9 ± 4.0 <0.001 
Male 645 (81.9%) 536 (79.6%) 343 (62.7%) <0.001 
BMI, kg/m2 28.7 ± 5.9 28.0 ± 5.0 26.1 ± 4.4 <0.001 
Heart rate, bpm 83.5 ± 21.5 80.9 ± 20.7 80.2 ± 19.4 0.007 
SBP, mmHg 121.6 ± 21.0 125.1 ± 20.8 126.6 ± 20.7 <0.001 
Inpatient 520 (66.0%) 407 (60.5%) 349 (63.8%) 0.091 
NYHA III/IV 470 (59.6%) 401 (59.6%) 364 (66.5%) 0.018 
Peripheral edema 477 (60.5%) 418 (62.1%) 380 (69.5%) 0.003 
Prior HFH (last 12mo) 250 (31.7%) 237 (35.2%) 188 (34.4%) 0.34 
Ischemic HF 305 (38.7%) 315 (46.8%) 296 (54.1%) <0.001 
PCI/CABG 226 (28.7%) 245 (36.4%) 207 (37.8%) <0.001 
Atrial fibrillation 248 (31.5%) 345 (51.3%) 274 (50.1%) <0.001 
Diabetes 221 (28.0%) 250 (37.1%) 181 (33.1%) <0.001 
COPD 103 (13.1%) 137 (20.4%) 102 (18.6%) <0.001 
Stroke 51 (6.5%) 68 (10.1%) 59 (10.8%) 0.009 
Peripheral arterial disease 67 (8.5%) 76 (11.3%) 56 (10.2%) 0.20 
Anemia 101 (12.8%) 168 (25.0%) 156 (28.5%) <0.001 
Urea, mmol/L 14.5 ± 11.3 15.7 ± 10.4 16.3 ± 10.5 0.005 
eGFR, ml/min/1.73m2 75.9 ± 21.8 59.7 ± 20.4 52.5 ± 19.5 <0.001 
Albumin, g/L 33.9 ± 8.1 32.4 ± 8.5 31.0 ± 8.6 <0.001 
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NT-pro BNP, pg/mL 1916 (779-4210) 2600 (1106-5639) 3570 (1655-7574) <0.001 
Legend: BMI, body mass index; SBP, systolic blood pressure; HF, heart failure; PCI/CABG, 
percutaneous coronary intervention/coronary artery bypass grafting; eGFR, estimated 
glomerular filtration rate using the CKD-EPI formula; HFH, heart failure hospitalization. P-
















Table 2.  Biomarkers independently associated with older age and corrected for test 
multiplicity (FDR1%) in both BIOSTAT-CHF and Dundee-HF (double cross-validation) 
Biomarker 
Age >75yr vs. <65yr (ref.) 
Βeta coef. (95%CI) P-value 
DCN 2.08 (1.62-2.55) <0.00001 
IL17D 1.67 (1.26-2.09) <0.00001 
MMP12 0.60 (0.43-0.77) <0.00001 
IGFBP2 0.62 (0.43-0.81) <0.00001 
OPG 0.70 (0.48-0.91) <0.00001 
TIMP4 0.57 (0.38-0.76) <0.00001 
RSPO3 0.47 (0.31-0.63) <0.00001 
CHIT1 0.26 (0.16-0.37) <0.00001 
MB 0.38 (0.23-0.54) <0.00001 
NOTCH3 0.49 (0.29-0.69) <0.00001 
TNFSF13 0.73 (0.40-1.06) 0.00001 
TREM1 0.64 (0.35-0.94) 0.00002 
FCRL6 0.42 (0.21-0.62) 0.00007 
PPY 0.24 (0.12-0.37) 0.00011 
SCF 0.45 (0.22-0.68) 0.00014 
ITGB5 0.69 (0.33-1.06) 0.00017 
TF 0.68 (0.32-1.04) 0.00024 
AMBP 0.94 (0.43-1.44) 0.00026 
CXCL13 0.34 (0.15-0.53) 0.00049 
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WFDC2 0.62 (0.23-1.00) 0.00166 
TGFR2 0.52 (0.19-0.85) 0.00182 
PRELP 0.72 (0.26-1.18) 0.00213 
ERBB3 -1.45 (-1.89 to -1.00) <0.00001 
CLEC4G -0.91 (-1.22 to -0.59) <0.00001 
ERBB2 -1.04 (-1.40 to -0.67) <0.00001 
HAOX1 -0.20 (-0.29 to -0.11) 0.00002 
SIT1 -0.56 (-0.82 to -0.30) 0.00002 
The coefficients and respective 95% confidence intervals here shown are those from the 
BIOSTAT-CHF cohort. These biomarkers were also independently associated with older age 
at a 1% false discovery rate correction in the Dundee cohort (please see the supplemental 
material for full results).  
Legend: DCN, decorin; IL17D, interleukin 17d; MMP12, matrix metalloproteinase 12; 
IGFBP2, insulin growth factor binding-protein 2; OPG, osteoprotegerin; TIMP4, 
metalloproteinase inhibitor 4; RSPO3, R-spondin-3; CHIT1, chitotriosidase-1; MB, myoglobin; 
NOTCH3, neurogenic locus notch homolog protein 3; TNFSF13, tumor necrosis factor ligand 
superfamily member 13; TREM1, triggering receptor expressed on myeloid cells 1; FCRL6, fc 
receptor-like protein 6; PPY, pancreatic prohormone; SCF, stem cell factor; ITGB5, integrin 
beta-5; TF, TF protein; AMBP, alpha-1-microglobulin/bikunin precursor; CXCL13, C-X-C motif 
chemokine 13; WFDC2, WAP four-disulfide core domain protein 2; TGFR2, TGF-beta 
receptor type-2; PRELP, prolargin; ERBB3, receptor tyrosine-protein kinase erbB-3; CLEC4G, 
c-type lectin domain family 4; ERBB2, receptor tyrosine-protein kinase erbB-2; HAOX1, 






Table 3. Biomarkers independently associated with older age and the study outcomes, fully 
adjusted and corrected for test multiplicity (FDR1%) both in BIOSTAT-CHF and Dundee-HF  
Biomarker HR (95%CI) P-value 
All-cause death or HF hospitalization 
WFDC2 2.53 (2.01-3.18) <0.00001 
PRELP 2.15 (1.66-2.79) <0.00001 
TREM1 1.56 (1.33-1.83) <0.00001 
ITGB5 1.55 (1.28-1.87) 0.00001 
CXCL13 1.23 (1.12-1.34) 0.00002 
All-cause death 
WFDC2 3.34 (2.46-4.52) <0.00001 
DCN 2.54 (1.90-3.38) <0.00001 
TNFSF13 2.28 (1.77-2.95) <0.00001 
TREM1 1.87 (1.52-2.29) <0.00001 
RSPO3 1.24 (1.13-1.36) <0.00001 
PRELP 2.10 (1.51-2.93) 0.00001 
CXCL13 1.28 (1.14-1.43) 0.00004 
ITGB5 1.66 (1.30-2.12) 0.00005 
OPG 1.32 (1.14-1.52) 0.0002 
NOTCH3 1.23 (1.07-1.40) 0.0025 
SCF 0.76 (0.66-0.88) 0.0003 
Cardiovascular death 
WFDC2 2.96 (2.05-4.29) <0.00001 
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TNFSF13 2.29 (1.68-3.12) <0.00001 
TREM1 1.79 (1.39-2.31) 0.00001 
CXCL13 1.28 (1.12-1.48) 0.0005 
RSPO3 1.22 (1.09-1.36) 0.0007 
ITGB5 1.65 (1.22-2.22) 0.001 
Non-cardiovascular death 
WFDC2 1.79 (1.46-2.20) <0.00001 
IGFBP2 1.61 (1.27-2.05) 0.0001 
TREM1 2.03 (1.41-2.91) 0.0001 
TNFSF13 2.25 (1.44-3.53) 0.0004 
DCN 2.51 (1.50-4.20) 0.0004 
PRELP 2.71 (1.52-4.82) 0.0007 
OPG 1.53 (1.20-1.96) 0.0008 
TGFR2 1.98 (1.30-3.03) 0.0015 
RSPO3 1.29 (1.11-1.51) 0.0017 
Legend: WFDC2, WAP four-disulfide core domain protein 2; PRELP, prolargin; TREM1, 
triggering receptor expressed on myeloid cells 1; ITGB5, integrin beta-5; CXCL13, C-X-C motif 
chemokine 13; DCN, decorin; TNFSF13, tumor necrosis factor ligand superfamily member 
13; RSPO3, R-spondin-3; OPG, osteoprotegerin; NOTCH3, neurogenic locus notch homolog 




Figure 1. Overall physical interaction with the age-significant predictors 
(A) Protein-pathway representation of the biomarkers positively associated with older 
age 
 
(B) Protein-pathway representation of the biomarkers negatively associated with older 
age 
 
(C) “KEGG” molecular interaction, reaction and relation networks of the expressed 
biomarkers 
 
Legend: Main networks and central-hubs of N1-physical interactions enrichment of age-
positive and age-negative protein predictors in patients with heart failure and reduced 
ejection fraction (n =1,611 in the BIOSTAT-CHF index cohort and n =823 in the BIOSTAT-CHF 
validation cohort). There are two “main theme” pathways: constitutive signaling by aberrant 
PI3K in cancer and renal cell carcinoma. 
Annotations are based on Gene Ontology, KEGG and Reactome pathways as source 
databases. These three resources were updated on 26-March-2020 before the analyses. 
Software versions ClueGO v2.5.6; CluePedia v1.5.6.  P-values were obtained from Go-terms 





Central Illustration. Main findings of the study  
 
Legend: ↑, up-regulated; ↓, down-regulated; HFrEF, heart failure with reduced ejection 
fraction.  
These findings can be applied to patients with heart failure and reduced ejection fraction (n 
=1,611 in the BIOSTAT-CHF index cohort and n =823 in the BIOSTAT-CHF validation cohort). 
 
 
